Susquehanna International Group
GLUE icon

Susquehanna International Group’s Monte Rosa Therapeutics GLUE Stock Holding History

Susquehanna International Group’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$407K Buy
24,751
+13,844
+127% +$265K ﹤0.01% 10164
2025
Q4 		$171K Sell
10,907
-5,279
-33% -$71.1K ﹤0.01% 11042
2025
Q3 		$120K Sell
16,186
-43,164
-73% -$229K ﹤0.01% 11451
2025
Q2 		$268K Buy
59,350
+6,012
+11% +$26.8K ﹤0.01% 10598
2025
Q1 		$247K Buy
53,338
+32,816
+160% +$201K ﹤0.01% 10494
2024
Q4 		$142K Buy
+20,522
New +$154K ﹤0.01% 11061
2024
Q1 		– Sell
-46,387
Closed -$275K – 12596
2023
Q4 		$262K Buy
+46,387
New +$182K ﹤0.01% 10115
2023
Q2 		– Sell
-13,111
Closed -$84.8K – 12458
2023
Q1 		$102K Buy
+13,111
New +$91.2K ﹤0.01% 11279
2022
Q4 		– Sell
-18,916
Closed -$158K – 12869
2022
Q3 		$155K Sell
18,916
-7,498
-28% -$68.9K ﹤0.01% 11188
2022
Q2 		$255K Buy
+26,414
New +$265K ﹤0.01% 9997

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Susquehanna International Group's GLUE Position: Q1 2026 in Review

Susquehanna International Group increased its Monte Rosa Therapeutics (GLUE) stake by 127% in Q1 2026, buying an estimated $265K and bringing the position to 24,751 shares worth $407K. The position accounts for ﹤0.01% of the portfolio, ranked #10164.

Susquehanna International Group first reported a position in GLUE in Q2 2022 and has held it in 10 quarters since. 191 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • Susquehanna International Group held 24,751 shares of Monte Rosa Therapeutics worth $407K as of Q1 2026.
  • Susquehanna International Group bought 13,844 Monte Rosa Therapeutics shares in Q1 2026, an estimated $265K.
  • Monte Rosa Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #10164 holding.
  • Susquehanna International Group first reported a position in Monte Rosa Therapeutics in Q2 2022 and has held it in 10 quarters since.
  • 191 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.